ORTHOCELL LIMITED — Capital/Financing Update 2025

Feb 17, 2025

==> picture [594 x 107] intentionally omitted <==

Notice under Section 708A(5)(e) of the Corporations Act

18 February 2025: Orthocell Limited ASX: OCC, “Orthocell” or “the Company”) is pleased to advise that it has today issued 1,273,363 fully paid ordinary shares ( Shares ) following the exercise of 500,000 $0.60 26 May 2026 unlisted options, 400,000 $0.403 13 July 2025 unlisted options and the cashless exercise of 500,000 $0.41 11 June 2025 unlisted options.

The Company gives notice under section 708(5)(e) of the Corporations Act 2001 (Cth) (“ Act ”) that:

• (a) the Shares were issued without disclosure to investors under Part 6D.2 of the Act;

• (b) the notice is being given under section 708A(5)(e) of the Act;

• (c) as at the date of this notice the Company has complied with:

  • (i) the provisions of Chapter 2M of the Act, as they apply to the Company; and

  • (ii) sections 674 and 674A of the Act; and

• (d) as at the date of this notice, there is no information that is ‘excluded information’ within the meanings of sections 708(A)(7) and 708A(8) of the Act that is required to be set out in this notice.

Release authorised by the Board of Orthocell Limited.

For more information, please contact:

General & Investor enquiries Media enquiries Paul Anderson Haley Chartres Orthocell Limited H^CK Director Managing Director P: +61 8 9360 2888 P: +61 423 139 163

• E: paul.anderson@orthocell.com.au E: haley@hck.digital

About Orthocell Limited

ACN 118 897 135 Registered Office – Building 191 Murdoch University, 90 South Street, Murdoch WA 6150 Australia

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Orthocell’s portfolio of products include CelGro™ platform of collagen medical devices which facilitate tissue reconstruction and healing in a variety of dental and orthopaedic reconstructive applications. Striate+™ was the first product approved for dental GBR applications, is cleared for use in US FDA (510k), Australia (ARTG) and Europe (CE Mark) and is distributed globally by BioHorizons Implant Systems Inc. Remplir™, for peripheral nerve reconstruction, recently received approval and reimbursement in Australia and is distributed exclusively by Device Technologies in the Australian market. SmrtGraft™, for tendon repair, is available in Australia under Special Access Scheme or participation in a clinical trial. The Company’s other major products are autologous cell therapies which aim to regenerate damaged tendon and cartilage tissue. Orthocell is accelerating the development of its tendon cell therapy in the US with technology transfer, manufacturing scale up and FDA engagement in advance of a randomised controlled study under FDA supervision.

For more information on Orthocell, please visit www.orthocell.com or follow us on Twitter @Orthocellltd and LinkedIn www.linkedin.com/company/orthocell-ltd

Ph: +61 8 9360 2888 Fax: +61 8 9360 2899 www.orthocell.com.au